sj-docx-1-msj-10.1177_13524585221102584 – Supplemental material for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Supplemental material, sj-docx-1-msj-10.1177_13524585221102584 for Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial by Bruce AC Cree, Krzysztof W Selmaj, Lawrence Steinman, Giancarlo Comi, Amit Bar-Or, Douglas L Arnold, Hans-Peter Hartung, Xavier Montalbán, Eva K Havrdová, James K Sheffield, Neil Minton, Chun-Yen Cheng, Diego Silva, Ludwig Kappos and Jeffrey A Cohen in Multiple Sclerosis Journal